Currently, there are 56.47M common shares owned by the public and among those 32.05M shares have been available to trade.
The company’s stock has a 5-day price change of 19.24% and 48.42% over the past three months. DSGN shares are trading 112.83% year to date (YTD), with the 12-month market performance up to 112.83% higher. It has a 12-month low price of $1.96 and touched a high of $5.48 over the same period. DSGN has an average intraday trading volume of 180.24K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.14%, 27.52%, and 62.84% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Design Therapeutics Inc (NASDAQ: DSGN) shares accounts for 41.68% of the company’s 56.47M shares outstanding.
It has a market capitalization of $319.34M and a beta (3y monthly) value of 1.78. The earnings-per-share (ttm) stands at -$0.90. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.36% over the week and 8.71% over the month.
Earnings per share for the fiscal year are expected to increase by 23.25%, and -28.47% over the next financial year.
Looking at the support for the DSGN, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on May 07, 2024, with the firm’s price target at $6-$12. Piper Sandler coverage for the Design Therapeutics Inc (DSGN) stock in a research note released on November 14, 2023 offered a Neutral rating with a price target of $6. Wedbush was of a view on August 15, 2023 that the stock is Neutral, while SVB Securities gave the stock Market Perform rating on August 15, 2023, issuing a price target of $6. RBC Capital Mkts on their part issued Sector Perform rating on August 15, 2023.
